Isolation and Characterization of Two Novel Bacteria *Afipia cberi* and *Mesorhizobium hominis* from Blood of a Patient Afflicted with Fatal Pulmonary Illness

Shyh-Ching Lo*, Bingjie Li¹, Guo-Chuan Hung¹, Haiyan Lei¹, Tianwei Li¹, Jing Zhang¹, Kenjiro Nagamine**, Shien Tsai¹, Mark J. Zucker², Ludmilla Olesnicky³

1 Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America, 2 Department of Medicine, Newark Beth Israel Medical Center, Newark, New Jersey, United States of America, 3 Department of Pathology, Newark Beth Israel Medical Center, Newark, New Jersey, United States of America

Abstract

We recently isolated and discovered new *Bradyrhizobiaceae* microbes from the cryopreserved culture broth of blood samples from 3 patients with poorly defined illnesses using modified SP4 media and culture conditions coupled with genomic sequencing. Using a similar protocol, we studied a previously cryopreserved culture broth of blood sample from a patient who had succumbed to an acute onset of fulminant pulmonary illness. We report that two phases of microbial growth were observed in the re-initiated culture. Biochemical and genomic characterization revealed microbes isolated from the first phase of growth were new *Afipia* species of *Bradyrhizobiaceae*, tentatively named *A. cberi* with a ~5 MB chromosome that was different from those of all previously known *Afipia* microbes including the newly discovered *A. septicum*. The microbes isolated from the second phase of growth were prominent sugar assimilators, novel *Phyllobacteriaceae*, phylogenetically most closely related to *Mesorhizobium* and tentatively named *M. hominis* with a ~5.5 MB chromosome. All *A. cberi* isolates carry a circular ~140 KB plasmid. Some *M. hominis* isolates possess a circular ~412 KB plasmid that can be lost in prolonged culture or passage. No antibiotics resistant genes could be identified in both of the *A. cberi* and *M. hominis* plasmids. Antibiotic susceptibility studies using broth culture systems revealed isolates of *A. cberi* could be sensitive to some antibiotics, but all isolates of *M. hominis* were resistant to essentially all tested antibiotics. However, the cell-free antibiotics susceptibility test results may not be applicable to clinical treatment against the microbes that are known to be capable of intracellular growth. It remains to be determined if the 2 previously unknown *Rhizobiales* were indeed pathogenic and played a role in the pulmonary disease process in this patient. Specific probes and methods will be developed to re-examine the diseased lungs from patient's autopsy.

Citation: Lo S-C, Li B, Hung G-C, Lei H, Li T, et al. (2013) Isolation and Characterization of Two Novel Bacteria *Afipia cberi* and *Mesorhizobium hominis* from Blood of a Patient Afflicted with Fatal Pulmonary Illness. PLoS ONE 8(12): e82673. doi:10.1371/journal.pone.0082673

Editor: Patrick M Schlievert, University of Iowa Carver College of Medicine, United States of America

Received August 30, 2013; Accepted October 25, 2013; Published December 18, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: The study was supported in part by FDA Modernizing Science Intramural Grant entitled “A new approach of detection and/or discovery of previously unknown pathogens”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: shyhching.lo@fda.hhs.gov
** Current address: Department of Oral & Maxillofacial Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

Introduction

The isolation of microbial pathogens by culture is crucial for clinical diagnosis in medical microbiology; however, microbial culture systems developed in the laboratory do not truly replicate the complex and dynamic properties of various tissues in human body. Some microbes fail to proliferate or grow to a detectable concentration in the axenic cultures used in the laboratory to grow and isolate the microbes. The newly developed next generation sequencing (NGS) technology has provided a revolutionary tool for the field of metagenomics through identification of unknown infectious microbes in a “culture-free” or “uncultured” condition [1,2]. The rapid advancements of NGS were used successfully in detecting and analyzing very low numbers of gene sequences of previously uncultivated microbes in an examined sample [3–5].

The new microbial detection capabilities of NGS technology have prompted us to re-examine some of our cryopreserved broth of blood cultures that were suspected of having low numbers of unknown, inactive microbes despite negative result of microbial isolation. These blood samples were previously submitted to the Laboratory of Infectious Diseases Pathology at
Armmed Forces Institute of Pathology (AFIP) for diagnostic consultations [6] and detection of possible unusual infections, such as mycoplasmal agents [7,8]. Encouraged by our recent success of isolating novel Afipia septicemium and identifying previously unknown Bradyrhizobium sp. OHSU-III from the cryopreserved SP4 broth of blood cultures from 3 patients with poorly defined illnesses [9], we decided to examine the cryopreserved SP4 culture broth from one particular patient’s blood sample submitted from Newark Beth Israel Medical Center (NBIMC) in 1999. The blood sample was obtained from a previously healthy 36 year-old white male right before he succumbed to an acute onset of a fulminating pulmonary illness. This highly unusual case with subsequent autopsy examination was studied extensively at NBIMC and AFIP without successfully identifying any etiological agent. The cause of death was reported to be necrotizing pneumonitis of presumably viral origin.

In this study we report isolation of 2 previously unknown Rhizobiales bacteria in the re-initiated blood-sample culture from this patient. Metabolic and genomic characterizations revealed that microbes isolated from the 1st phase of growth (NBIMC_P1) in culture were new Afipia sp. in the Family of Bradyrhizobiales and microbes isolated from the 2nd phase of growth (NBIMC_P2) in culture were new Phyllobacteriaceae, most closely related to those of Mesorhizobium sp. We have also examined antibiotics susceptibilities of the 2 novel microbes isolated from the patient blood.

Materials and Methods

Studying previously frozen cultures of the blood samples was conducted under FDA Research Involving Human Subjects Committee (RIHSC) protocol 10-008B entitled “Detection of Infectious Agents in Previously Frozen Blood Samples from Patients with Various Illnesses and Healthy Blood Donors”. The original clinical presentations of patients were provided by Dr. Zucker in this study after the IRB of NBIMC and Bamabas Health Corporate legal representatives reviewed and determined that the activity did not meet the definition of human subject research per 45 CFR 46.102(d), a written informed consent from the patient was waived. The clinical illness was described in the study without revealing the patient’s identity.

Blood sample, patient and clinical presentation

A 36-year old previously healthy white male woke up with a headache and fever after playing golf the day before. The patient went to see his primary care physician who prescribed the antibiotic “levofloxacin”. The patient did not improve clinically and developed a macular rash. His physician changed the antibiotics to “amoxicillin/clavulanic acid”. Despite the antibiotics targeting both bacteria and Rickettsia were begun and additional laboratory studies were sent to the local laboratory and to the AFIP in the hope of identifying an infectious agent. Despite the ECMO and the antibiotics, the patient’s clinical condition progressively deteriorated and he expired 2 weeks after admission to NBIMC. An autopsy was conducted in less than 4 hours. However, no etiologic cause was identified. The AFIP pathology report also concluded that no infectious agent was identified.

Broth medium and agar plates

Preparation of the modified SP4 medium with new supplements and other microbial broths as well as agar plates was previously described in detail [9].

Microbial cultures

(1): Original microbial cultures for diagnostic study. The laboratory received 600 to 700 µL partially hemolyzed whole blood (WB) for the diagnostic study in 1999. Details of protocol for isolation of mycoplasmal agents were previously described [7]. For this particular sample, 100 µL of WB were inoculated into a culture tube containing 5 mL SP4 broth medium supplemented with 10% fetal bovine serum (FBS). In addition, 50 µL of WB were streaked on an individual SP4 agar plate and BHI agar plate. Four separate sets of SP4 broth cultures and agar plates were set up and kept respectively in either an aerobic condition or in GasPack, at 37 °C or at 32 °C. For each set of cultures set up, 2 (negative) control cultures containing the same amount of broth without inoculation of the specimen to be examined were included and studied in parallel. Aliquots of broth were routinely streaked on SP4 agar plates and BHI agar plates and were tested by PCR assays using mycoplasma-specific primers at different intervals of sample cultivation during the months-long follow-up. The broth samples were also routinely examined for color changes and by dark-field/phase-contrast microscopy for evidence of microbial growth. At the end of diagnostic study, the SP4 broth of the culture kept at 32 °C in GasPack was suspected of having a low number of unknown microbes and was mixed with glycerol (final ~ 10%) and cryopreserved at -80 °C.

(2): Re-initiated microbial cultures for microbial isolation. The procedures of re-initiating previously cryopreserved SP4 broth culture and examination for evidence of microbial growth were described in detailed [9]. Briefly, cryopreserved SP4 broth (100 to 200 µL) containing cultures established from blood samples were inoculated into 25 cm2 tissue culture flasks containing ~ 7 mL of modified SP4 medium supplemented with 10% irradiated FBS. Three sets of cultures were kept separately at room temperature (RT, ~ 25 °C), 30 °C and 35 °C. For each set of cultures, at least 2 control cultures containing the same modified SP4 broth medium and FBS were inoculated with frozen plasma and 0.3 X 106 of PBMC from healthy blood donors and studied in parallel. None of the control cultures showed microbial growth in the study.

Biochemical and metabolic study using Bio-Log ID system, electron microscopy study, whole genome
sequencing, 16S rRNA gene and rDNA operon comparison and phylogenetic analysis

The studies were conducted as previously described [9]. The GenBank Accession Numbers for NBIMC_P1-C1, NBIMC_P1-C2, NBIMC_P1-C3, NBIMC_P2-C1, NBIMC_P2-C2, NBIMC_P2-C3 and NBIMC_P2-C4 are AVBK00000000, AVBL00000000, AVBM00000000, AVBN00000000, AVBO00000000, AVBP00000000 and AVBQ00000000, respectively.

Construction of draft genomes and genome content comparison

Alignment of the formed contigs assembled from genomic sequencing into draft genomes for Afipia sp. NBIMC_P1 isolates was previously described in detail [9]. The complete genome of Mesorhizobium loti (GenBank accession number NC_002678.2) was used as a reference genome in draft genome construction for NBIMC_P2 isolates. As described in the previous study [9], the schematic sequence alignment for all input draft genome sequences using CONTIGuator [10] and comparison of dissimilarity for genome contents among the related microbes were performed using progressiveMauve [11].

Antibiotic susceptibility test

Antibiotic susceptibility tests for each antibiotic were performed in triplicates using marcobroth dilution method [12] in 24-well plates. Logarithmically growing bacteria (1.5 × 10^8 c.f.u/mL, final concentration) were inoculated into each well of 2 mL of YM broth containing ranged concentrations of each antibiotic tested. MIC (minimum inhibition concentration) was read on the plates incubated at 30 °C for 72 h and 48 h for Afipia sp. isolates and Mesorhizobium sp. isolates, respectively. Escherichia coli (E. coli) ATCC 25922 and Staphylococcus aureus (S. aureus) ATCC 29213 were studied in parallel as the quality control for the antibiotics potency. All antibiotics tested in this study were purchased from Sigma-Aldrich Co. (St. Louis, MO).

Results

Growth and isolation of microbes from cryopreserved cultures of NBIMC blood sample

The re-initiated blood cultures using modified SP4 broth kept separately at room temperature (RT, ~ 25 °C), 30 °C and 35 °C were examined under an inverted microscope 2 to 3 times a week. The cultures initially showed no sign of microbial growth. The broths of the cultures streaked on SP4-agar and BHI-agar plates also produced no detectable colonies. However, cultures kept at RT began to show sign of microbial growth after ~ 10 weeks. The cultures were diluted 1:3 with fresh modified SP4 media and expanded into 3 flasks. The microbes in these cultures gradually grew into a plateau containing higher cell density with low, but detectable turbidity in the broth after additional 3 to 4 weeks. Gram staining revealed the microbes in the broths were Gram-negative bacteria. The broths of the cultures streaked on SP4-agar plates also started to produce microscopic colonies. The colonies could be detected under microscope on the agar plates kept at RT for ~ 1-2 weeks (Figure 1 A). Individual microscopic colonies were picked with care and grown in cultures using modified SP4 broth media with or without supplement of FBS at RT (Figure 1B). The colony-derived microbes adapted well enough to grow in YM broth without supplement of FBS. The bacteria derived from individual colonies picked on agar plate (NBIMC_P1-C1, P1-C2 and P1-C3) were studied for biochemical reactions and metabolic property testing as well as whole-genome sequencing. None of the control cultures set up with the same SP4 broth containing irradiated FBS and followed in parallel showed evidence of microbial growth in the study.

Unexpectedly, in the continual follow-up, the SP4 broth cultures kept at RT gave signs of having an apparent 2nd phase of microbial growth ~ 5 weeks after microbes were isolated from the initial phase (Phase 1, P1) of growth. Growth of microbes in the 2nd phase (Phase 2, P2) reached a significantly higher plateau of cell density than that in the P1, produced more prominent turbidity and acidity color change in the broth. Gram staining revealed the more rapidly proliferating microbes in the cultures were also Gram-negative bacteria. The culture broths streaked on SP4 agar produced colonies clearly larger than those formed previously from microbes of the 1st phase of growth (Figure 1C). The colonies were detectable after 5-7 days by the naked eye appearing to be lightly yellowish or brownish in color. Individual colonies were again picked and grown at RT in broth cultures using modified SP4 broth media, with or without supplement of FBS (Figure 1D). The bacteria derived from the selected colonies of Phase 2 growth (NBIMC_P2-C1, P2-C2, P2-C3 and P2-C4) were also examined for biochemical properties and by whole-genome sequencing. As described in the Materials/Methods, for each sample-testing culture, at least 2 negative control cultures were set up in parallel using the same culture media and kept together at each respective temperature and culture conditions. None of these control cultures grew any microbes.

Biochemical characterization using Bio-Log identification system

NBIMC_P1-C1, P1-C2 and P1-C3 cloned from the Phase 1 growth could grow on BCYE agar, YM agar or SP4 agar kept at both 30 °C and 35 °C. The microbes could also grow on agar plates made using tissue culture medium RPMI-1640 with 5% fetal bovine serum at 37 °C in a CO2 incubator. In comparison, NBIMC_P2-C1, P2-C2, P2-C3 and P2-C4 cloned from the Phase 2 growth could only grow on YM and BCYE agars kept at 32 °C (BCYE agars at 33 °C) and did not grow well on these agars kept at 35 °C (Table 1). The microbes obtained from both the 1st and the 2nd phases of growth in the culture could not grow on MacConkey agar kept at any temperature tested. Biochemical properties and metabolic characterization of representative single-colony cloned were studied using Biolog bacterial identification system. The system offers phenotype microarrays that enable microbes to be evaluated for thousands of phenotypes under thousands of culture conditions. In the study, all bacteria isolates were first grown on YM or BCYE agar plates for 7 days at 30 °C and then transferred to the Biolog micro-plates for metabolic testing.
Most significantly, results of the studies for sugar assimilations by the microbes including glucose, arabinose, mannose, mannitol and N-acetyl glucosamine showed that all the isolates/clones from the 1st phase growth tested negative and all the isolates/clones from the 2nd phase growth tested positive (Table 1: [13,14]). However, the metabolic test results of the isolates obtained from both the 1st and the 2nd phases (NBIMC_P1 and NBIMC_P2) of growth in the culture did not match well with any specific bacterium in the Biolog identification database. The biochemical characterization study produced no identification match for NBIMC_P1 isolates in the database. The study for NBIMC_P2 isolates had a partial match of 33% to 50% similarity with *Aminobacter aminovorans*, in the Family of *Phyllobacteriaceae*, Order of *Rhizobiales*.

**Ultrastructure study of microbial isolates from the 1st and the 2nd phases of growth in culture**

The single-colony cloned bacteria from culture broth showing the 1st phase of microbial growth (NBIMC_P1-C2) and single-colony cloned bacteria from culture broth showing the 2nd
| Tests                               | Afipia cberi | Mesorhizobium hominis | Studies Results of References |
|-------------------------------------|--------------|-----------------------|-------------------------------|
|                                     | NBIMC_P1 | NBIMC_P2 | Aminobacteraminovorans# | Mesorhizobium loti* | Mesorhizobium amorphae* | Bradyrhizobium japonicum* | Agrobacterium radiobacter |
| Growth on:                          |           |           |                     |                  |                        |                            |                            |
| BCYE agar (RT)                      | P         | P         | P                   | P                 | P                      | P                           | P                           |
| 30 °C                               | P         | P         | P                   | P                 | P                      | P                           | P                           |
| 32 °C                               | P         | P         | P                   | P                 | P                      | P                           | P                           |
| 33 °C                               | P         | P         | P                   | P                 | P                      | P                           | P                           |
| 35 °C                               | P         | P         | N                   | N                 | N                      | N                           | P                           |
| 37 °C                               | N         | N         | N                   | N                 | N                      | N                           | N                           |
| YM agar (RT)                        | P         | P         | P                   | P                 | P                      | P                           | P                           |
| 30 °C                               | P         | P         | P                   | P                 | P                      | P                           | P                           |
| 32 °C                               | P         | P         | P                   | P                 | P                      | P                           | P                           |
| 33 °C                               | P         | P         | N                   | N                 | N                      | N                           | P                           |
| 35 °C                               | P         | P         | N                   | N                 | N                      | N                           | P                           |
| 37 °C                               | N         | N         | N                   | N                 | N                      | N                           | N                           |
| Columbia agar_5% SB (30 °C)         | N         | N         | N                   | P                 | N                      | N                           | P                           |
| 32 °C                               | N         | N         | N                   | P                 | P                      | P                           | P                           |
| 33 °C                               | N         | N         | N                   | N                 | N                      | N                           | N                           |
| 34 °C                               | N         | N         | N                   | N                 | N                      | N                           | N                           |
| Chocolate agar (RT)                 | N         | N         | N                   | P                 | P                      | P                           | P                           |
| 30 °C                               | N         | N         | N                   | P                 | P                      | P                           | P                           |
| 32 °C                               | N         | N         | N                   | P                 | P                      | P                           | P                           |
| 33 °C                               | N         | N         | N                   | N                 | N                      | N                           | N                           |
| BHI agar (RT)                       | N         | N         | N                   | N                 | N                      | N                           | N                           |
| 30 °C                               | N         | N         | N                   | P                 | P                      | P                           | P                           |
| 32 °C                               | N         | N         | N                   | P                 | P                      | P                           | P                           |
| 33 °C                               | N         | N         | N                   | N                 | N                      | N                           | N                           |
| RPMI-5% FBS 35 °C/CO2 incubator     | P         | P         | P                   | N                 | N                      | N                           | N                           |
| 37 °C                               | P         | P         | P                   | N                 | N                      | N                           | N                           |
| MacConkey agar (RT)                 | N         | N         | N                   | N                 | N                      | N                           | N                           |
| Tests          | Afipia cberi | *Mesorhizobium hominis* | Studies | Results of References |
|---------------|--------------|-------------------------|---------|-----------------------|
|               | NBIMC_P1     | NBIMC_P2                |         |                       |
|               | C1    | C2    | C3    | C1    | C2    | C3    | C4    | Amino bacteraminovorans# | Mesorhizobium loti* | Mesorhizobium amorphae* | Bradyrhizobium japonicum* | Agrobacterium radiobacter |
| 30°C          | N     | N     | N     | N     | N     | N     | N     |                       |                       |                       |                       |                        |
| 35 °C         | N     | N     | N     | N     | N     | N     | N     |                       |                       |                       |                       |                        |
| Nitrate reduction | p   | N     | N     | N     | N     | N     | N     | P                       | P                       | P                       | P                       |                        |
| Catalase      | p     | p     | p     | p     | p     | p     | p     | P                       | p                       | p                       | P                       |                        |
| Oxidase       | P     | P     | P     | P     | P     | P     | P     | P                       | p                       | p                       | P                       |                        |
| Assimilation of: |       |       |       |       |       |       |       |                       |                       |                       |                       |                        |
| Glucose       | N     | N     | N     | P     | P     | P     | P     | P                       |                       |                       |                       |                        |
| Arabinose     | N     | N     | N     | P     | P     | P     | P     | P                       |                       |                       |                       |                        |
| Mannose       | N     | N     | N     | P     | P     | P     | P     | N                       |                       |                       |                       |                        |
| Mannitol      | N     | N     | N     | P     | P     | P     | P     | N                       |                       |                       |                       |                        |
| N-Acetylglucosamine | N   | N     | N     | P     | P     | P     | P     | N                       |                       |                       |                       |                        |
| Gluconate     | p     | p     | p     | P     | P     | P     | P     | N                       |                       |                       |                       |                        |
| Malate        | N     | p     | p     | N     | N     | N     | N     | N                       |                       |                       |                       |                        |
| D-Malic acid  | N     | N     | N     | N     | N     | N     | N     | N                       |                       |                       |                       |                        |
| L-Malic acid  | N     | p     | p     | N     | N     | N     | N     | N                       |                       |                       |                       |                        |
| Citrate       | N     | N     | N     | N     | N     | N     | N     | N                       |                       |                       |                       |                        |
| Phenylacetate | P     | P     | P     | p     | N     | p     | p     | N                       |                       |                       |                       |                        |
| Raffinose     | N     | N     | N     | N     | N     | N     | N     | N                       |                       |                       |                       |                        |
| Lactose       | N     | N     | N     | N     | N     | N     | N     | P                       | P                       | N                       |                       |                        |
| Melibiose     | N     | N     | N     | N     | N     | N     | N     | P                       | P                       | P                       | P                       |                        |
| D-Galactose   | N     | N     | N     | N     | N     | N     | N     | P                       | P                       | P                       | P                       |                        |
| L-Rhamnose    | N     | N     | N     | P     | P     | P     | P     | P                       | P                       | N                       |                       |                        |
| Maltose       | N     | N     | N     | P     | P     | P     | P     | P                       | N                       | N                       | P                       |                        |
| D-Trehalose   | N     | N     | N     | P     | P     | P     | P     | P                       | P                       | N                       | P                       |                        |
| Sucrose       | N     | N     | N     | P     | P     | P     | P     | P                       | P                       | N                       | P                       |                        |
| D-Cellbiose   | N     | N     | N     | P     | P     | P     | P     | P                       |                       |                       |                       |                        |
| D-Sorbitol    | N     | N     | N     | P     | P     | P     | P     | N                       |                       |                       |                       |                        |
| Propionic acid | N     | N     | N     | N     | N     | N     | N     | P                       |                       |                       |                       |                        |
### Table 1 (continued).

| Tests          | Afipia cberi | Mesorhizobium hominis | Studies Results of References |
|----------------|--------------|-----------------------|------------------------------|
|                | NBIMC_P1     | NBIMC_P2              | Amino bacteraminovorans[^#]  |
|                | C1           | C2                    | Mesorhizobium loti' amorphae'|
|                | C3           | C1                    | Bradyrhizobium japonicum'    |
|                | C2           | C2                    | Agrobacterium radiobacter    |
| Biolog ID      | N/A          | N/A                   | Aminobacter aminovorans      |
| (%) similarity | 33%          | 43%                   | 38%                          |
| G+C content (%)| 61.5%        | 61.5%                 | 63.4%                        |

[^#]: International Journal of Systematic and Evolutionary Microbiology (2005), 55, 1827–1832 (Ref 13)
[^*]: International Journal of Systematic and Evolutionary Microbiology (2001), 51, 1011–1021 (Ref 14)

*P = positive, p = weak positive, N = negative, N/A = not available*
phase of microbial growth (NBIMC_P2-C1) were subjected for ultra-structure study by electron microscopy. Both of the bacteria were grown in SP4 broth, concentrated by centrifugation and fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer. Figures 2A and 2B show the thick sections for concentrated samples of the two different bacteria embedded in epoxy resin. NBIMC_P1-C2 microbes appeared to be more slender and pointed bacteria. In comparison, many of the rod-shaped NBIMC_P2-C1 microbes looked slightly larger or thicker. The sections of both NBIMC_P1-C2 and NBIMC_P2-C1 revealed occasional microbes that appeared to be more pleomorphic in shape and larger in size. The ultra-thin sections revealed unique ribosomal structures, occasional electron-dense bodies, fine nucleic acid structures and differences in bacterial wall structures of the 2 different microbes obtained from the 1\textsuperscript{st} and the 2\textsuperscript{nd} phases of growth in the culture (Figures 2C and 2D). Atypical outer membranes of Gram-negative bacterial wall structures were seen in some NBIMC_P2-C1 microbes (Figure 2D). The more round and pleomorphic microorganisms had less-ribbed and noticeably wavy outer membranes in their wall structures (Figure 2E).

Whole genome sequencing of isolates from the 1\textsuperscript{st} and the 2\textsuperscript{nd} phases of microbial growth in broth culture

Whole-genome sequencing of single colony-derived isolates cloned from the 1\textsuperscript{st} phase (NBIMC_P1-C1, P1-C2 and P1-C3) and the 2\textsuperscript{nd} phase (NBIMC_P2-C1, P2-C2, P2-C3 and P2-C4) of microbial growths in blood culture was conducted using the Illumina MiSeq platform (Table 2). The raw reads generated from each bacterial isolate in genomic sequencing were first assembled into contigs using CLC Bio Genomics Workbench bioinformatic tool.

(1): Whole genome sequencing analysis of the 1\textsuperscript{st} phase growth isolates. The genomic sequencing result revealed total contig lengths of formed contigs from all 3 single-colony cloned isolates of the 1\textsuperscript{st} phase microbial growth were ~5 million base pairs (Mb) (Table 2). The GC content of the presumed ~5 Mb microbial genome was 61.5%. The sequences obtained for each of the 3 isolates had the average of 141 to 160-fold coverage of the draft genomes.

Analysis of 16S rRNA gene and rDNA operon sequences: The sequences of 16S rRNA gene (~1.4 Kb) as well as the whole rDNA operon (~5.4 Kb) from the 3 single-colony cloned isolates of the initial phase of growth (NBIMC_P1) were found to be identical. Comparison of the 16S rRNA gene and whole rDNA operon sequences with those in the NCBI database showed the 3 single-colony-cloned isolates of NBIMC_P1 were microbes in the Family of Bradyrhizobiaceae, closely related to those of Afipia species (Figure 3A and B). The microbes in the genus and even the family are known to have very high levels of homology in their 16S rRNA gene sequences. As such, these sequences are not good indicators to determine species or genera diversity [12,15]. Since all Bradyrhizobiaceae have their 3 rRNA genes similarly organized and co-transcribed as an operon, analysis based on the variations in sequences of 5.4 Kb rDNA operons could be much more informative in the study of highly challenging Bradyrhizobiaceae taxonomy [9]. Analysis of the rDNA operon sequences revealed that NBIMC_P1 isolates are phylogenetically most closely related to A. broomae, followed by our recently isolated A. septicemium [9]. They are more distant from A. clevelandensis, A. birgae and A. massiliensis, and most distant from A. felis (Figure 3B).

Analysis of genome sequences: We constructed draft genomes for A. cberi strains NBIMC_P1-C1, P1-C2 and P1-C3 by assembling the formed contigs using CONTIGuator tool [10] as described in our recent publication [9]. The complete genome of Bradyrhizobiaceae bacterium strain SG-6C [16] and the working complete genome of A. broomae [17] served as the references. Figure 4A shows sequence mapping of closely related NBIMC_P1-C2, A. septiciem and A. broomae genomes with regions of difference identified using CGView program [18]. Blank color regions of marked sequence difference could clearly be identified between genomes of NBIMC_P1-C2 and A. septiciem as well as between genomes of NBIMC_P1-C2 and A. broomae. Comparison for the similarity or dissimilarity of genome content among draft genomes of different isolates NBIMC_P1-C1, C2 and C3, and those of A. septiciem as well as other 5 established Afipia sp. was conducted by using theinformatics tool progressiveMauve [11]. The genome comparison revealed the 3 single-colony clones of NBIMC_P1-C1, C2 and C3 were highly similar to each other in their genome content (GC content of 61.5%), with a dissimilarity value less than 0.2% (Table 3). The NBIMC_P1 isolates appeared to be most closely related to A. broomae, but the 2 microbes still had ~12% of dissimilarity in their respective genome content. The NBIMC_P1 isolates should represent a new Afipia species, tentatively named A. cberi in this study. In comparison, A. cberi NBIMC_P1 isolates and the recently discovered strains OHSU_I and OHSU_II of A. septiciem had ~23% dissimilarity in genome content. There is significantly higher dissimilarity (~30%) in genome content between A. cberi and A. clevelandensis or A. birgae. The isolates of A. cberi are genetically most distant (~45%) from A. felis. Our genomic sequencing analysis and comparison among NBIMC_P1 isolates and established Afipia sp. revealed the 3 single-colony cloned A. cberi NBIMC_P1 isolates carry a ~140 Kb circular plasmid, pAC140. The circular plasmid could not be found in other established Afipia sp. and not in A. septiciem OHSU_I or OHSU_II isolates (Figure 4B). However, its sequence was found to have high homology with a ~128 Kb gene segment designated previously as supercontig 1.4 in a reported A. broomae draft genome [17]. As described in our previous study [9], this particular gene segment of A. broomae was suspected to be a plasmid, because it revealed significant homology with several plasmids of alpha-2 proteobacteria in Blastn search against GenBank database. The A. cberi plasmid pAC140 (GC content of 62.6%) has coding regions of 120,609 bp (86.3% of the plasmid) with no RNA gene, 155 predicted protein-coding genes and 89 proteins with known functions. But, analysis showed no identifiable antibiotic resistant gene. Sequence comparison of pAC140 with A. broomae supercontig 1.4 shows that pAC140 carries additional 2 gene segments with overall ~9.5 Kb sequences that are not present in supercontig 1.4, the presumed plasmid
of *A. broomeae* (Figure 4B). Blastn search revealed the 2 gene segments had homology with putative ABC transporter and integrase-transposase genes.

(2): **Whole genome sequencing analysis of the 2nd phase growth isolates.** The total contig lengths of formed contigs from all 4 single-colony cloned isolates of the 2nd phase microbial growth (NBIMC_P2-C1, P2-C2, P2-C3 and P2-C4) were ~ 5.5 Mb or ~ 5.9 Mb (Table 2). Two clones with the presumed genome size of ~ 5.9 Mb had GC content of 63.1% and the other 2 clones with the presumed genome size of ~ 5.5 Mb had GC content of 63.4%. The sequences obtained for each of the 4 isolates had the average of 300 to 735-fold of the presumed genome coverage.

**Analysis of 16S rRNA gene and rDNA operon sequences:** Sequencing results showed all 4 single-colony cloned isolates from the 2nd phase growth (NBIMC_P2) had the identical 16S rRNA gene and the whole rDNA operon sequences. Phylogenetic comparison of the sequences of

![Image of NBIMC_P1 and NBIMC_P2 microbes](image-url)

*Figure 2. Thick section photomicrographs and ultrathin electron micrographs of NBIMC_P1 and NBIMC_P2 microbes. A and B: Thick section photomicrographs of NBIMC_P1-C1 and NBIMC_P2-C2 cultures using modified SP4 broth. The section of concentrated NBIMC_P1-C1 reveals slender pointed microbes (A). The section of concentrated NBIMC_P2-C2 reveals slightly larger or thicker rods (B). Both sections show some microbes (arrows) that are more polymorphic in shape and larger in size with longitudinal and cross sectioning. The concentrated microbes were fixed with 2.5 % glutaraldehyde, post-fixed with 1% osmium tetroxide and embedded in epoxy resin. The thick sections were stained using 1% tolue blue. 1000X. C and D: Electron photomicrographs of NBIMC_P1-C1 (C) and NBIMC_P2-C2 (D) captured in ultrathin sections. Typical Gram-negative bacteria wall structure (short arrows), intracellular ribosomal structures (R), electron-dense bodies and nucleic acid (N) as well as scale bars are indicated for both sections. Atypical wall structures with loose and wavy outer membranes are seen in some of NBIMC_P2-C2 microbes (long arrow). The ultrathin sections were stained with uranyl acetate and lead citrate. E: Electron micrograph of NBIMC_P2-C2 microbes that are more polymorphic in shape captured at higher magnification. External membrane (arrow) of the Gram-negative bacteria wall structure appeared to be less rigid and wavy. The scale bar is indicated.*

doi: 10.1371/journal.pone.0082673.g002
NBIMC_P2 isolates with those deposited in the NCBI database revealed the isolates are a previously unknown species of bacteria related to those of Mesorhizobium in the Family of Phyllobacteriaceae (Figure 5). Figure 5A shows the phylogenetic tree based on heterogeneity in sequences of 16S rRNA genes submitted to NCBI. Figure 5B shows the phylogenetic analysis of sequences of rDNA operons among these isolates and established species of Mesorhizobium with their genomic sequences available in NCBI. We tentatively named the NBIMC_P2 isolates, the first Mesorhizobium isolated from humans, Mesorhizobium hominis in this study.

Analysis of genome sequences: We constructed draft genomes for all the 4 single-colony-cloned NBIMC_P2 isolates of M. hominis using the complete genome of M. loti as reference [17]. An apparent difference in total length of the formed contigs from genomic sequencing of these 4 single-colony-cloned isolates was noticed (Table 2). The difference (~5.94 Mb of NBIMC_P2-C1 and P2-C4 versus ~5.54 Mb of NBIMC_P2-C3 and NBIMC_P2-C4) was found to be the result of growth of the plasmid-containing isolates/clones of M. hominis in culture would apparently result in quickly losing the plasmid.

|          | C1 clone | C2 clone | C3 clone | C4 clone |
|----------|----------|----------|----------|----------|
| No. of raw reads | 6,759,170 | 4,842,336 | 4,166,696 | 9,200,992 |
| Total reads length (bp) | 7,98{2}67,429 | 768,566,565 | 706,133,276 | 1,789,380,704 |
| No. of qualified reads | 6,716,274 | 4,747,508 | 4,135,906 | 9,174,760 |
| No. of reads in contigs | 6,646,354 | 4,685,007 | 4,093,548 | 9,087,368 |
| No. of contigs formed | 89 | 66 | 69 | 92 |
| Max contig length | 402,855 | 548,545 | 548,545 | 345,443 |
| N50 | 124,487 | 223,703 | 166,412 | 166,173 |
| Total contig length | 4,996,310 | 4,996,867 | 4,996,806 | 5,948,199 |
| Estimated coverage | 160 | 154 | 141 | 300 |
| GC contents (%) | 61.5 | 61.5 | 61.5 | 63.1 |

Table 2. Whole genome sequencing datasets of single-colony cloned microbes from the 1st phase (P1) and the 2nd phase (P2) microbial growth in NBIMC blood culture.

doi: 10.1371/journal.pone.0082673.t002

Comparison for the similarity or dissimilarity of contents among draft chromosomal genomes of the 4 single-colony-cloned isolates of M. hominis and those of established Mesorhizobium sp. was conducted by usinginformatics tool progressiveMauve. The comparison revealed the contents of genomes for 4 single-colony cloned isolates from NBIMC_P2 were highly similar to one another, with dissimilarity less than 0.2% (Table 4). However, genome contents of M. hominis isolates had a dissimilarity of ~62.3 % with that of M. loti. They also had very high dissimilarity (62 to 68.3%) with those of other established Mesorhizobium, including M. opportunistum, M. amorphae, M. australicum and M. alhagi (Table 4).

Antibiotic susceptibility study

We conducted an in vitro antibiotic susceptibility study for the newly discovered microbes of A. cberi and M. hominis using broth culture system with serial dilutions of antibiotics [12]. The study revealed microbial isolates of A. cberi were susceptible to penicillin G, cephalothin, ceftriaxone, cefoxitin, rifampicin and streptomycin based on the minimal inhibition concentrations...
of these antibiotics. Our recently discovered *A. septicemium* OHSU_I and OHSU_II strains were also found to be susceptible to these antibiotics, but not to streptomycin. However, microbial isolates of *M. hominis* with or without the presence of plasmid pMH412.1 were not susceptible to nearly all the antibiotics tested including the antibiotics commonly

Figure 3. **Phylogenetic relatedness of *Afipia cberi* NBIMC_P1 isolates among *Afipia* sp. and *Bradyrhizobium* sp. microbes.** Phylogenetic analysis for NBIMC_P1 isolates based on 16S rRNA gene sequences (A) and whole rDNA operon sequences (B) using the neighbor-joining method. GenBank Accession numbers of sequences used in the analyses are shown in parentheses. Scale bar units are estimated branch lengths. Numerals indicate bootstrap percentages over 50 after 500 replications. doi: 10.1371/journal.pone.0082673.g003
used to treat intracellular bacterial infections such as doxycycline and tetracycline (Table 5). Only the MIC of cefoxitin indicated microbial isolates of *M. hominis* could be considered marginally sensitive to the antibiotic. *Escherichia coli* (E. coli) ATCC 25922 and *Staphylococcus aureus* (S. aureus) ATCC 29213 were studied in parallel as the quality control for expected potency of the testing antibiotics against the drug-sensitive bacteria.

**Table 3.** Genome content differences among *Afipia cberi* NBIMC_P1 isolates, established *Afipia* species, *Afipia septicemium* OHSU_I-C4, OHSU_II-C1 and *Bradyrhizobiaceae* SG.

|          | 1    | 2    | 3    | 4    | 5    | 6    | 7    | 8    | 9    | 10   | 11   |
|----------|------|------|------|------|------|------|------|------|------|------|------|
| 1. *A. cberi* NBIMC_P1-C1 | -    | 0.16%| 0.10%| 22.81%| 22.83%| 11.95%| 30.04%| 29.99%| 44.59%| 43.43%| 29.90%|
| 2. *A. cberi* NBIMC_P1-C2 | 0.16%| -    | 0.09%| 22.82%| 22.84%| 11.96%| 30.06%| 30.00%| 44.61%| 43.44%| 29.93%|
| 3. *A. cberi* NBIMC_P1-C3 | 0.10%| 0.09%| -    | 22.79%| 22.81%| 11.92%| 30.03%| 29.98%| 44.59%| 43.43%| 29.90%|
| 4. *A. septicemium* OHSU_I-C4 | 22.81%| 22.82%| 22.79%| -    | 0.03%| 22.38%| 30.43%| 30.63%| 44.88%| 43.21%| 30.34%|
| 5. *A. septicemium* OHSU_II-C1 | 22.83%| 22.84%| 22.81%| 0.03%| -    | 22.45%| 30.45%| 30.65%| 44.89%| 43.23%| 30.36%|
| 6. *A. broomeae* | 11.95%| 11.96%| 11.92%| 22.38%| 22.45%| -    | 31.16%| 30.66%| 45.10%| 44.05%| 30.89%|
| 7. *A. clevelandensis* | 30.04%| 30.06%| 30.03%| 30.43%| 30.45%| 31.16%| -    | 32.22%| 44.92%| 43.89%| 30.14%|
| 8. *A. birgiae* | 29.99%| 30.00%| 29.98%| 30.63%| 30.65%| 30.66%| 32.22%| -    | 45.31%| 44.46%| 32.16%|
| 9. *A. felis* | 44.59%| 44.61%| 44.59%| 44.88%| 44.89%| 45.10%| 44.92%| 45.31%| -    | 27.01%| 44.74%|
| 10. *Afipia* sp. 1NLS2 | 43.43%| 43.44%| 43.43%| 43.21%| 43.23%| 44.05%| 43.89%| 44.46%| 27.01%| -    | 43.73%|
| 11. *Bradyrhizobiaceae* SG | 29.90%| 29.93%| 29.90%| 30.34%| 30.36%| 30.89%| 10.14%| 32.16%| 44.74%| 43.73%| -    |

Rows 1-11 correspond to columns 1-11.

doi: 10.1371/journal.pone.0082673.t003
In this study we describe finding a mixed infection by 2 different Rhizobiales in the blood sample culture broth from a patient who succumbed to a fulminant course of progressive lung disease in 1999. A 2nd phase of microbial growth (NBIMC_P2) was observed nearly 2 months later after the 1st phase of microbial growth (NBIMC_P1) occurred. In comparison with A. cberi isolated from the initial phase of growth, NBIMC_P2 microbes apparently stayed longer in an inactive state, but grew faster and could reach into a significantly higher cell density plateau in the microbial culture system once they underwent proliferation. Genomic characterization demonstrated they are novel Phyllobacteriaceae, phylogenetically most related to those of Mesorhizobium. This is evidently the first Mesorhizobium-related microbe isolated from humans, thus the NBIMC_P2 isolates are tentatively referred to as strains of M. hominis in Figure 5.

Figure 5A Phylogenetic relatedness of M. hominis NBIMC_P2 isolates based on heterogeneity of 16S rRNA gene sequences among Mesorhizobium

Figure 5B Phylogenetic relatedness of M. hominis NBIMC_P2 based on heterogeneity of rDNA operon sequences among Mesorhizobium

Discussion

In this study we describe finding a mixed infection by 2 different Rhizobiales in the blood sample culture broth from a patient who succumbed to a fulminant course of progressive lung disease in 1999. A 2nd phase of microbial growth (NBIMC_P2) was observed nearly 2 months later after the 1st phase of microbial growth (NBIMC_P1) occurred. In comparison with A. cberi isolated from the initial phase of growth, NBIMC_P2 microbes apparently stayed longer in an inactive state, but grew faster and could reach into a significantly higher cell density plateau in the microbial culture system once they underwent proliferation. Genomic characterization demonstrated they are novel Phyllobacteriaceae, phylogenetically most related to those of Mesorhizobium. This is evidently the first Mesorhizobium-related microbe isolated from humans, thus the NBIMC_P2 isolates are tentatively referred to as strains of M. hominis in
this study. However, there are marked sequence heterogeneities of 16S rRNA genes and rDNA operons as well as significant differences in genome contents between \textit{M. hominis} NBIMC\_P2 and established \textit{Mesorhizobium} species (Figure 5 and Table 4). \textit{M. hominis} could prove to be microbes that are separated taxonomically from the Genus of \textit{Mesorhizobium} after further studies.

Genomic studies revealed all 3 isolates or clones of \textit{A. cberi} possess a previously unknown stable circular ~ 140 Kb plasmid, pAC140. No plasmid has previously been reported in

Table 4. Genome content differences among NBIMC\_P2 isolates and established \textit{Mesorhizobium} species.

|          | 1  | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|----------|----|---|---|---|---|---|---|---|---|----|
| 1. \textit{M. hominis} NBIMC\_P2-C1 | -  | 0.13% | 0.13% | 0.14% | 62.28% | 62.28% | 62.48% | 62.00% | 68.30% | 62.62% |
| 2. \textit{M. hominis} NBIMC\_P2-C2 | 0.13% | - | 0.14% | 0.14% | 62.27% | 62.28% | 62.47% | 62.00% | 68.31% | 62.64% |
| 3. \textit{M. hominis} NBIMC\_P2-C3 | 0.13% | 0.14% | - | 0.10% | 62.29% | 62.29% | 62.48% | 62.00% | 68.31% | 62.64% |
| 4. \textit{M. hominis} NBIMC\_P2-C4 | 0.14% | 0.14% | 0.10% | - | 62.29% | 62.30% | 62.48% | 62.01% | 68.32% | 62.65% |
| 5. \textit{M. loti} | 62.28% | 62.27% | 62.29% | 62.29% | - | 39.86% | 41.28% | 43.12% | 67.11% | 48.98% |
| 6. \textit{M. opportunistum} | 62.28% | 62.28% | 62.29% | 62.30% | 39.86% | - | 34.05% | 35.06% | 67.08% | 49.96% |
| 7. \textit{M. australicum} | 62.48% | 62.47% | 62.48% | 62.46% | 41.28% | 34.05% | - | 35.61% | 67.46% | 51.07% |
| 8. \textit{M. ciceri} | 62.00% | 62.00% | 62.00% | 62.01% | 43.12% | 35.06% | 35.61% | - | 66.89% | 49.47% |
| 9. \textit{M. alhagi} | 68.30% | 68.31% | 68.31% | 68.32% | 67.11% | 67.08% | 67.46% | 66.89% | - | 66.13% |
| 10. \textit{M. amorphae} | 66.62% | 62.64% | 62.64% | 62.65% | 48.98% | 49.69% | 51.07% | 49.47% | 66.13% | - |

Rows 1-10 correspond to columns 1-10.
doi: 10.1371/journal.pone.0082673.t004

Figure 6. Sequence mapping for the draft genome of \textit{Mesorhizobium hominis} NBIMC\_P2 and its circular plasmid pMH412. (A) Sequence mapping for the draft genome of \textit{M. hominis} NBIMC\_P2-C3 against those of \textit{M. hominis} NBIMC\_P2-C4 and complete genome of \textit{M. loti} including 2 plasmids pMLa and pMLb. The tracks from inside to outside represent GC skews, GC contents, draft genome of NBIMC\_P2-C3 microbe, draft genome of NBIMC\_P2-C4 microbe and \textit{M. loti} genome. The color blank regions represent sequence differences found between the bacterial genomes. Major regions of difference are seen in the regions of 0.4-0.5 Mb, 0.6-0.7 Mb, 1.8-1.9 Mb, 2.3-2.4 Mb and 3.1-3.2 Mb. (B) Sequence mapping for the circular plasmid pMH412 against the formed contigs of NBIMC\_P2-C3, NBIMC\_P2-C4 and complete genome of \textit{M. loti} genome including pMLa and pMLb. The tracks from inside to outside represent GC skews, GC contents, formed contigs with draft genome of NBIMC\_P2-C3, NBIMC\_P2-C4 and \textit{M. loti} complete genome including pMLa and pMLb. Most of the tracks representing formed contigs of NBIMC\_P2-C3 and \textit{M. loti} genome including pMLa and pMLb are blank. Sequence of pMH412 can only be mapped with the formed contigs from NBIMC\_P2-C4, not with the formed contigs from NBIMC\_P2-C3 or \textit{M. loti} complete genome with pMLa and pMLb.
doi: 10.1371/journal.pone.0082673.g006
any established species of *Afipia*. However, as described in our previous study [9], the reported supercontig 1.4 of *A. bromeae* [17] would likely represent an unrecognized plasmid. Sequence comparison has identified 2 additional gene segments with total ~ 9.5 Kb sequences in pAC140, evidently not present in supercontig 1.4, the presumed plasmid, or in the entire formed contigs of *A. bromeae* (Figure 4B). Detail of *A. cberi* genome and plasmid structures will be presented separately. Interestingly, genomic sequencing study of *M. hominis* obtained from the 2nd phase microbial growth in culture revealed that some clones/isolates also had a circular ~ 412.1 Kb plasmid, pMH412. However, clones of *M. hominis* tested positive for pMH412 were found to quickly lose the plasmid when the bacteria were kept for prolonged culturing or undergoing continual cell passage. The instability of extrachromosomal plasmids was reported previously in some of the *Rhizobial* microbes [20,21]. The significance in biology and in clinical implications of the 2 plasmids identified in *A. cberi* and *M. hominis* is not clear at this moment. The possible virulence effects of these plasmids including antibiotics susceptibilities of the bacteria and their potential pathogenic association with infections in humans will require further studies.

Testing of antibiotic susceptibility for *A. cberi* and *M. hominis* isolates revealed the microbes particularly those of *M. hominis* appear to be resistant to most of the commonly used antibiotics (Table 5). Since *Afipia*, *Bradyrhizobium* and *Mesorhizobium* are a group of microbes that are potentially able to invade, survive and grow in eukaryotic cells, antibiotic susceptibility results from the tests conducted in cell-free microbial cultures against these facultative intracellular microbes may not be applicable clinically to the treatment of infected patients. Development of a better drug sensitivity assay system that is more relevant to the in vivo condition of intracellular infections by these microbes will be more ideal. However, for *M. hominis* that are not susceptible to nearly all the antibiotics tested in a cell-free microbial culture system, they are likely to be even less

### Table 5. Antibiotic susceptibility study for microbial isolates of *Afipia* species and *Mesorhizobium* species.

| Antibiotics | *Afipia cberi* | *Afipia septicum* | *Mesorhizobium hominis* | *E. coli* | *S. aureus* |
|-------------|----------------|-------------------|------------------------|-----------|------------|
|             | NBIMC_P1-C1 | NBIMC_P1-C2 | OHSU_I-C4 | OHSU_II-C2 | NBIMC_P2-C1 | NBIMC_P2-C2 | NBIMC_P2-C3 | NBIMC_P1-C4 | ATCC 25922 | ATCC 29213 |
| Penicillin G | 2              | 2               | 2           | 1          | 64         | 64         | 128        | 64         | 32         | 0.25       |
| Amoxicillin | 64             | 64              | 64          | 64         | 64         | 64         | 64         | 64         | 2          | 0.5        |
| AMC         | 1              | 1               | 1           | 1          | 64         | 64         | 64         | 64         | 2          | 0.5        |
| Ampicillin  | 8              | 8               | 8           | 8          | 16         | 8          | 8          | 64         | 2          | 0.5        |
| Piperacillin| 4              | 4               | 8           | 8          | 128        | 128        | 128        | 64         | 4          | 1          |
| Cefoxitin   | 1              | 1               | 1           | 1          | 4          | 8          | 8          | 4          | 8          | 2          |
| Cephalothin | 0.25           | 0.25            | 0.5         | 0.5        | 64         | 64         | 64         | 64         | 8          | 0.12       |
| Ceftriaxone | 0.5            | 0.5             | 0.5         | 0.5        | 16         | 64         | 128        | 16         | 0.25       | 1          |
| Imipenem    | 8              | 8               | 8           | 8          | 16         | 16         | 16         | 32         | 0.12       | 0.03       |
| Amikacin    | 8              | 8               | 8           | 8          | 32         | 64         | 64         | 64         | 2          | 4          |
| Kanamycin   | 8              | 8               | 8           | 8          | 128        | 128        | 128        | 128        | 4          | 8          |
| Gentamicin  | 32             | 32              | 16          | 16         | 8          | 8          | 8          | 8          | 4          | 8          |
| Streptomycin| 4              | 4               | 64          | 32         | >128       | >128       | >128       | >128       | 1          | 4          |
| Tetracycline| 8              | 8               | 32          | 32         | 8          | 8          | 16         | 8          | 0.5        | 0.12       |
| Doxycycline | 8              | 8               | 32          | 32         | 16         | 16         | 16         | 32         | 32         | 0.5        |
| Ciprofloxacin| 4             | 4               | 16          | 16         | 8          | 4          | 8          | 8          | 0.12       | 0.25       |
| Levofloxacin| 8              | 8               | 32          | 32         | 16         | 16         | 16         | 16         | 0.03       | 0.03       |
| Rifampicin  | 2              | 2               | 2           | 1          | 16         | 4          | 4          | 4          | 4          | 0.015      |
| Erythromycin| 32             | 32              | 128         | 128        | >128       | >128       | >128       | >128       | 128        | 1          |
| TMP-SMX     | 32             | 32              | 32          | 32         | 64         | 64         | 64         | 64         | 2          | 2          |
| Vancomycin  | 64             | 64              | >128        | 128        | 32         | 32         | 32         | >128       | 0.5        |

Values are MIC (mg/l). AMC: Amoxicillin/Clavulanic acid (2:1), TMP-SMX: Trimethoprim/sulfamethoxazole (1:5). The results of AMC and TMP-SMX are the MICs of Amoxicillin and Trimethoprim.

* The isolation and characterization of *A. septicum* was described in Ref #9.

doi: 10.1371/journal.pone.0082673.r005
Rhizobium and other members of the Families of Bradyrhizobiaceae and Phyllobacteriaceae [22,23], some *Afipia* species of *Bradyrhizobium* [24] and *Rhizobium* (Agrobacterium) radiobacter of *Rhizobiaceae* [25–27] infect humans and produce various acute and chronic forms of illnesses. However, most members of *Bradyrhizobium* in the Family of Bradyrhizobiaceae and members of *Mesorhizobium* in the Family of Phyllobacteriaceae were generally known as soil bacteria [28]. On the other hand, microbes in this unique group of *Rhizobiales* are facultative intracellular microbes that could effectively invade and grow in eukaryotic host cells [29]. The symbiotic *Bradyrhizobium* and *Mesorhizobium* microbes utilize amino acids from plant cells to survive and grow, but provide the infected plants with much needed fixed-form of nitrogen by taking atmosphere free nitrogen and converting it into ammonia or ammonium [30]. It is important to note that none of the nif and nod genes or symbiosis Islands found in genomes of symbiotic nitrogen-fixation bacteria isolated from soil or plants are identified in the newly discovered *Bradyrhizobium* species OHSU-III [8] and *M. hominis*. However, similarities between the strategies adopted by pathogenic and symbiotic *Rhizobiales* in infecting the eukaryotic hosts have been described [29].

The findings of infections, in addition to new *Afipia* microorganisms, by novel microbes of *Bradyrhizobium* and *Mesorhizobium* in humans reveal a previously unrecognized host spectrum as well as nature of infections by microbes of *Bradyrhizobiaceae* and *Phyllobacteriaceae* Families in *Rhizobiales*. In this context, a recent sequences-based discovery of new *Bradyrhizobium enterica* in the biopsies of cord blood transplanted patients with cord colitis syndrome [31] is important in revealing infections of the otherwise unknown and uncultured *Bradyrhizobiaceae* bacteria in patients. The analysis of 16 S rRNA gene r-RNA operon sequences shows that *Bradyrhizobium enterica* and our recent culture-based identification of new *Bradyrhizobium* sp. OHSU-III [9] are phylogenetically closely related. Comparison of genome sequences (NCBI accession numbers: AMFBU0000000 and APJD0000000) using progressiveMauve shows the 2 new *Bradyrhizobium* microbes found infecting human hosts are more closely related to each other than to any other established species of *Bradyrhizobium* microbes. However, the 2 *Bradyrhizobium* are apparently different and possess ~30% dissimilarities between their genome contents. More novel species of *Bradyrhizobiaceae* and *Phyllobacteriaceae* microbes will likely be found infecting human hosts.

Importantly, isolations of these microbes from blood samples indicates these newly discovered *Rhizobiales*, like those human pathogenic microbes of *Brucellaceae*, *Bartonellaceae* and *Rhizobiaceae* Families in the *Rhizobiales*, could be related to hematogenous infections and could be disseminated systemically in the infected patients. Also significantly, the study has demonstrated that a patient could apparently be infected at the same time by a combination of 2 different *Rhizobiales* microbes. However, it is important to stress that it is presently unclear what the roles of these 2 newly discovered *Rhizobiales* played, if any, in this patient’s unrelenting respiratory distress illness. Follow-up studies including re-examination of the diseased lung tissues from patient’s autopsy could better unveil the possible role in the necrotizing process of infected lung for each of the microbe isolated. Successful growth and isolation of these previously unknown and uncultivated microbes by culture has made it possible to analyze metabolic and pathogenicity roles of the microbes in various chronic or acute forms of human disease processes. Many important questions including prevalence of infections, mode of transmission and diseases association can only be answered through further studies and development of better microbial, molecular, and serological assays against the newly identified microbes of *Rhizobiales*.

**Acknowledgements**

We thank Philip Yang for his helpful proof-reading and editing of the manuscript as well as his assistance in re-configuring some figures and tables presented in the paper.

**Author Contributions**

Conceived and designed the experiments: SCL BL GCH. Performed the experiments: SCL BL TL JZ KN ST. Analyzed the data: GCH HL. Contributed reagents/materials/analysis tools: MJZ LO. Wrote the manuscript: SCL GCH BL HL.

**References**

1. Bieseker LG (2012) Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med 14: 393-398. gim201178; 10.1038/gim.2011.76.
2. Didelot X, Bowden R, Wilson DJ, Peto TE, Crook DW (2012) Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 13: 601-612. nrgr3226;10.1038/ngr3226.
3. Albertsen M, Hugenholz P, Skaroshewski A, Nielsen KL, Tyson GW et al. (2013) Genome sequences of rare, uncultured bacteria obtained by differential coverage binning of multiple metagenomes. Nat Biotechnol 31: 533-538. nbt.2579;10.1038/nbt.2579.
4. Loman NJ, Constantinidou C, Christian M, Rohde H, Chan JZ et al. (2013) A culture-independent sequence-based metagenomics approach to the investigation of an outbreak of Shiga-toxigenic *Escherichia coli* O104:H4. JAMA 309: 1502-1510. 1677374;10.1001/jama.2013.3231.
5. Rinke C, Schwientek P, Sczyrba A, Ivanova NN, Anderson IJ et al. (2013) Insights into the phylogeny and coding potential of microbial dark matter. Nature . Nature12352. doi:10.1038/nature12352.
6. McCook A (2011) Death of a pathology centre: Shelved. Nature 476: 270-272. 476270a. doi:10.1038/476270a. PubMed:21850082.
7. Lo SC, Hayes MM, Wang RY, Pierce PF, Kotani H et al. (1991) Newly discovered mycoplasma isolated from patients infected with HIV. Lancet 338: 1415-1418. 0140-6736(91)92721-D.
8. Lo SC, Buchholz CL, Wear DJ, Hohm RC, Marty AM (1991) Newly discovered mycoplasma isolated from patients infected with HIV. Lancet 338: 1415-1418. 0140-6736(91)92721-D.
9. Lo SC, Hung GC, Li B, Lei HY, Li TW et al. (2013) Isolation of novel *Afipia septicemium* and identification of previously unknown bacteria *Bradyrhizobium* sp. OHSU-III from blood of patients with poorly defined
illnesses. PLOS ONE. 8(10): e76142. doi:10.1371/journal.pone.0076142. PubMed: 24155886.

10. Galardini M, Biondi EG, Bazzicalupo M, Mengoni A (2011) CONTIGUator: a bacterial genomes finishing tool for structural insights on draft genomes. Source Code Biol. Med 6: 11. doi: 10.1186/1751-0473-6-11.

11. Darling AE, Mau B, Perna NT (2010) progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. PLOS ONE 5: e11147. doi:10.1371/journal.pone.0011147. PubMed: 20593022.

12. La Scola B, Barrassi L, Raoult D (2000) Isolation of new fastidious α Proteobacteria and Afipia felis from hospital water supplies by direct plating and amoebal co-culture procedures. FEMS Microbiol Ecol 34: 129-137. S0168649600009842.

13. McDonald IR, Kampfer P, Topp E, Warner KL, Cox MJ et al. (2005) Aminobacter ciceronei sp. nov. and Aminobacter lissarensis sp. nov., isolated from various terrestrial environments. Int J Syst Evol Microbiol 55: 1827-1832. 55/5/1827;10.1099/ijs.0.63716-0.

14. Velázquez E, Igual JM, Willems A, Fernández MP, Muñoz E et al. (2001) Mesorhizobium chacoense sp. nov., a novel species that nodulates Prosopis alba in the Chaco Arido region (Argentina). Int J Syst Evol Microbiol 51: 1011-1021. doi:10.1099/0027713-51-3-1011. PubMed: 11411656.

15. Fox GE, Witoszky JD, Jurtshuk P Jr. (1992) How close is close: 16S rRNA sequence identity may not be sufficient to guarantee species identity. Int J Syst Bacteriol 42: 166-170. doi:10.1099/0022-1287 (1992)42[166-170]

16. Pearce SL, Pandey R, Dorrian SJ, Russell RJ, Oakeshott JG et al. (2011) Genome sequence of the newly isolated chemolithoautotrophic Proteobacteria and Afipia ciceronei strain SG-6C. J Bacteriol 193: 5057. JB. 55/5/5057;10.1128/jb.05847-11.

17. Afipia bromeae ATCC 49717 RefSeq Genome. Available: http://www.ncbi.nlm.nih.gov/nuccore/17048339. Accessed 2013 September 4

18. Grant JR, Stothard P (2008) The CGView Server: a comparative genomics tool for circular genomes. Nucleic Acids Res 36: 181-184. doi:10.1093/nar/gkn179. PubMed: 18411220.

19. Kaneko T, Nakamura Y, Sato S, Asamizu E, Kato T et al. (2000) Complete genome structure of the nitrogen-fixing symbiotic bacterium Mesorhizobium loti: DNA Res 7: 331-338. doi:10.1093/dnares/7.6.331. PubMed: 11214968.

20. Weaver RW (1999) Stability of plasmids in Rhizobium phaseoli during culture. Soil Biol, Biochem 22: 465-469. doi:10.1016/0038-0717(99)00179-4.

21. Lopez-Guerrero MG, Ormeno-Orell E, Acosta JL, Mendoza-Vargas A, Rogel MA et al. (2012) Rhizobial extrachromosomal replicon variability, stability and expression in natural niches. Plasmid 68: 149-158. S0147-619X(12)00079-0;10.1016/j.plasmid.2012.07.002.

22. Pulliainen AT, Deho C (2012) Persistence of Bartonella spp. stealth pathogens: from subclinical infections to vasoproliferative tumor formation. FEMS Microbiol Rev 36: 563-599. doi:10.1111/j.1574-6976.2012.00324.x. PubMed: 22229763.

23. Sohn AH, Probert WS, Glaser CA, Gupta N, Bollen AW et al. (2003) Human neurobrucellosis with intracerebral granuloma caused by a marine mammal Brucella spp. Emerg Infect Dis 9: 485-488: 485–8. doi: 10.3201/eid0904.020576. PubMed: 12702232.

24. Brenner DJ, Hollis DG, Moss CW, English CK, Hall GS et al. (1991) Proposal of Afipia gen. nov., with Afipia felis sp. nov. (formerly the cat scratch disease bacillus), Afipia clevelandensis sp. nov. (formerly the Cleveland Clinic Foundation strain), Afipia bromeae sp. nov., and three unnamed genospecies. J Clin Microbiol 29: 2450-2460. PubMed: 1774249.

25. Hulse M, Johnson S, Ferrieri P (1993) Agrobacterium infections in humans: experience at one hospital and review. Clin Infect Dis 16: 112-117. doi:10.1093/clinids/16.1.112. PubMed: 8448285.

26. Gibling MR, Grant JR, Tacket CO et al. (2000) Clinical and microbiological characteristics of Rhizobium radiobacter infections. Clin Infect Dis 38: 149-153. C1D19797:10.1086/308463.

27. Plotkin GR (1980) Agrobacterium radiobacter prosthetic valve endocarditis. Ann Intern Med 93: 839-840. PubMed: 7447191.

28. Weaver RW, Frederick (1972) A new technique for most probable-number counts of rhizobia. Plant and Soil 36: 219-222. doi:10.1007/BF01373474.

29. Batul J, Andersson SG, O’Callaghan D (2004) The evolution of chronic infection strategies in the alpha-proteobacteria. Nat Rev Microbiol 2: 933-945. nmicro1044;10.1038/nrmicro1044.

30. Graham PH (1998) Principals and applications of soil microbiology. In: Hall.

31. Bhatt AS, Freeman SS, Herrera AF, Pedamallu CS, Gevers D et al. (2013) Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med 369: 517-528. doi:10.1056/NEJMoa1211115. PubMed: 23924002.